Summary

The global oncology drugs market is undergoing a period of rapid expansion, fueled by continuous innovation in cancer therapeutics and a growing global disease burden. Oncology remains a critical focus area within the pharmaceutical industry, with companies striving to develop advanced treatment options that enhance patient survival and quality of life. Breakthroughs in immunotherapy, targeted therapy, and precision medicine have significantly transformed cancer treatment paradigms. As healthcare systems worldwide prioritize early detection and effective management of cancer, the demand for innovative oncology drugs continues to rise, positioning the market for sustained long-term growth.

Market Insights

The oncology drugs market is anticipated to increase from USD 287.1 billion in 2026 to USD 680.1 billion by 2033, expanding at a CAGR of 13.10% over the forecast period. This remarkable growth reflects a surge in cancer prevalence, increasing investments in oncology research, and the steady introduction of novel drug therapies. The market landscape is evolving with the integration of biologics, biosimilars, and next-generation therapies aimed at improving treatment efficacy. In addition, regulatory approvals for innovative drugs are accelerating, while healthcare providers are adopting advanced treatment protocols, further contributing to market expansion. Emerging economies are also playing a vital role due to improving access to healthcare and rising awareness about cancer treatment options.

Drivers

The rising incidence of cancer globally remains a key factor driving the oncology drugs market. Aging populations, unhealthy lifestyles, and environmental exposures are contributing to higher cancer rates, thereby increasing the demand for effective treatments. Technological advancements in molecular diagnostics and genomics are enabling the development of targeted therapies that offer improved precision and reduced side effects. The growing acceptance of immunotherapy, which harnesses the body’s immune system to fight cancer, is also a major growth driver. Furthermore, increased funding for cancer research, supportive government policies, and favorable reimbursement frameworks in developed countries are encouraging innovation and adoption of new therapies. Enhanced screening programs are leading to early detection, which further boosts the demand for oncology drugs.

Business Opportunity

The oncology drugs market presents extensive opportunities for stakeholders across the pharmaceutical and biotechnology sectors. The expanding pipeline of innovative therapies, including gene therapy and cell-based treatments, offers promising avenues for growth. Companies are actively engaging in strategic partnerships, licensing agreements, and acquisitions to strengthen their research capabilities and global footprint. The development of biosimilars is opening new pathways for cost-effective cancer treatments, particularly in emerging markets. In addition, the integration of artificial intelligence and big data analytics is streamlining drug discovery and clinical trial processes, enabling faster and more efficient development of oncology drugs. Increasing healthcare investments in developing regions are further enhancing market opportunities and encouraging global expansion.

Region Analysis

North America holds a leading position in the oncology drugs market, supported by advanced healthcare infrastructure, strong research capabilities, and significant healthcare spending. The presence of major pharmaceutical companies and early adoption of innovative treatments further strengthens the region’s dominance. Europe also represents a substantial market share, driven by increasing awareness, supportive healthcare policies, and expanding access to cancer care services. The Asia Pacific region is expected to exhibit the fastest growth during the forecast period, owing to a large patient base, improving healthcare systems, and growing investments in oncology research. Countries such as China and India are emerging as key contributors to regional growth. Meanwhile, Latin America and the Middle East & Africa are gradually expanding, supported by improvements in healthcare access and rising awareness about cancer treatment.

Key Players

The oncology drugs market is highly competitive, with leading companies focusing on innovation, product development, and strategic collaborations to maintain their market positions. Key players include:

• GlaxoSmithKline

• AstraZeneca plc

• AbbVie

• Pfizer Inc.

• Amgen Inc

• Gilead Sciences, Inc

• Hoffmann-La Roche Ltd

• Bristol-Myers Squibb Company (Celgene Corp)

• Novartis AG

• Johnson & Johnson Merck & Co.

• Eli Lilly and Company

• Sanofi S.A

• Bayer AG

These companies continue to invest in advanced research and clinical development to introduce new oncology treatments and strengthen their global presence.

Segmentation

By Drug Class

• Chemotherapy

o Alkylating Agents

o Antimetabolites

o Anti-tumour Antibiotics

o Topoisomerase Inhibitors

o Mitotic Inhibitors

o Others

• Targeted Therapy

o Monoclonal Antibodies

o Small molecule Inhibitors

• Immunotherapy

o Immune Checkpoint Inhibitors

o Cell Therapy and Gene Therapy

o Oncolytic Virus Therapy

o Immune System Modulators

• Hormonal Therapy

By Indication

• Breast Cancer

• Lung Cancer

• Prostate Cancer

• Multiple Myeloma

• Colorectal Cancer

• Non-Hodgkin's Lymphoma

• Kidney Cancer

• Chronic lymphocytic Leukaemia

• Melanoma

• Others

By Route of Administration

• Oral

• Injectable

By Distribution Channel

• Hospital Pharmacies

• Retail Pharmacies

• Others

By Region

• North America

• Europe

• Asia Pacific

• Latin America

• Middle East & Africa

ページTOPに戻る

Table of Contents

1. Executive Summary
1.1. Global Oncology Drugs Market Snapshot
1.2. Future Projections
1.3. Key Market Trends
1.4. Regional Snapshot, by Value, 2026
1.5. Analyst Recommendations
2. Market Overview
2.1. Market Definitions and Segmentations
2.2. Market Dynamics
2.2.1. Drivers
2.2.2. Restraints
2.2.3. Market Opportunities
2.3. Value Chain Analysis
2.4. COVID-19 Impact Analysis
2.5. Porter's Five Forces Analysis
2.6. Impact of Russia-Ukraine Conflict
2.7. PESTLE Analysis
2.8. Regulatory Analysis
2.9. Price Trend Analysis
2.9.1. Current Prices and Future Projections, 2025-2033
2.9.2. Price Impact Factors
3. Global Oncology Drugs Market Outlook, 2020 - 2033
3.1. Global Oncology Drugs Market Outlook, by Drug Class, Value (US$ Bn), 2020-2033
3.1.1. Chemotherapy
3.1.1.1. Alkylating Agents
3.1.1.2. Antimetabolites
3.1.1.3. Anti-tumour Antibiotics
3.1.1.4. Topoisomerase Inhibitors
3.1.1.5. Mitotic Inhibitors
3.1.1.6. Others
3.1.2. Targeted Therapy
3.1.2.1. Monoclonal Antibodies
3.1.2.2. Small molecule Inhibitors
3.1.3. Immunotherapy
3.1.3.1. Immune Checkpoint Inhibitors
3.1.3.2. Cell Therapy and Gene Therapy
3.1.3.3. Oncolytic Virus Therapy
3.1.3.4. Immune System Modulators
3.1.4. Hormonal Therapy
3.2. Global Oncology Drugs Market Outlook, by Indication, Value (US$ Bn), 2020-2033
3.2.1. Breast Cancer
3.2.2. Lung Cancer
3.2.3. Prostate Cancer
3.2.4. Multiple Myeloma
3.2.5. Colorectal Cancer
3.2.6. Non-Hodgkin's Lymphoma
3.2.7. Kidney Cancer
3.2.8. Chronic lymphocytic Leukaemia
3.2.9. Melanoma
3.2.10. Others
3.3. Global Oncology Drugs Market Outlook, by Route of Administration, Value (US$ Bn), 2020-2033
3.3.1. Oral
3.3.2. Injectable
3.4. Global Oncology Drugs Market Outlook, by Distribution Channel, Value (US$ Bn), 2020-2033
3.4.1. Hospital Pharmacies
3.4.2. Retail Pharmacies
3.4.3. Others
3.5. Global Oncology Drugs Market Outlook, by Region, Value (US$ Bn), 2020-2033
3.5.1. North America
3.5.2. Europe
3.5.3. Asia Pacific
3.5.4. Latin America
3.5.5. Middle East & Africa
4. North America Oncology Drugs Market Outlook, 2020 - 2033
4.1. North America Oncology Drugs Market Outlook, by Drug Class, Value (US$ Bn), 2020-2033
4.1.1. Chemotherapy
4.1.1.1. Alkylating Agents
4.1.1.2. Antimetabolites
4.1.1.3. Anti-tumour Antibiotics
4.1.1.4. Topoisomerase Inhibitors
4.1.1.5. Mitotic Inhibitors
4.1.1.6. Others
4.1.2. Targeted Therapy
4.1.2.1. Monoclonal Antibodies
4.1.2.2. Small molecule Inhibitors
4.1.3. Immunotherapy
4.1.3.1. Immune Checkpoint Inhibitors
4.1.3.2. Cell Therapy and Gene Therapy
4.1.3.3. Oncolytic Virus Therapy
4.1.3.4. Immune System Modulators
4.1.4. Hormonal Therapy
4.2. North America Oncology Drugs Market Outlook, by Indication, Value (US$ Bn), 2020-2033
4.2.1. Breast Cancer
4.2.2. Lung Cancer
4.2.3. Prostate Cancer
4.2.4. Multiple Myeloma
4.2.5. Colorectal Cancer
4.2.6. Non-Hodgkin's Lymphoma
4.2.7. Kidney Cancer
4.2.8. Chronic lymphocytic Leukaemia
4.2.9. Melanoma
4.2.10. Others
4.3. North America Oncology Drugs Market Outlook, by Route of Administration, Value (US$ Bn), 2020-2033
4.3.1. Oral
4.3.2. Injectable
4.4. North America Oncology Drugs Market Outlook, by Distribution Channel, Value (US$ Bn), 2020-2033
4.4.1. Hospital Pharmacies
4.4.2. Retail Pharmacies
4.4.3. Others
4.5. North America Oncology Drugs Market Outlook, by Country, Value (US$ Bn), 2020-2033
4.5.1. U.S. Oncology Drugs Market Outlook, by Drug Class, 2020-2033
4.5.2. U.S. Oncology Drugs Market Outlook, by Indication, 2020-2033
4.5.3. U.S. Oncology Drugs Market Outlook, by Route of Administration, 2020-2033
4.5.4. U.S. Oncology Drugs Market Outlook, by Distribution Channel, 2020-2033
4.5.5. Canada Oncology Drugs Market Outlook, by Drug Class, 2020-2033
4.5.6. Canada Oncology Drugs Market Outlook, by Indication, 2020-2033
4.5.7. Canada Oncology Drugs Market Outlook, by Route of Administration, 2020-2033
4.5.8. Canada Oncology Drugs Market Outlook, by Distribution Channel, 2020-2033
4.6. BPS Analysis/Market Attractiveness Analysis
5. Europe Oncology Drugs Market Outlook, 2020 - 2033
5.1. Europe Oncology Drugs Market Outlook, by Drug Class, Value (US$ Bn), 2020-2033
5.1.1. Chemotherapy
5.1.1.1. Alkylating Agents
5.1.1.2. Antimetabolites
5.1.1.3. Anti-tumour Antibiotics
5.1.1.4. Topoisomerase Inhibitors
5.1.1.5. Mitotic Inhibitors
5.1.1.6. Others
5.1.2. Targeted Therapy
5.1.2.1. Monoclonal Antibodies
5.1.2.2. Small molecule Inhibitors
5.1.3. Immunotherapy
5.1.3.1. Immune Checkpoint Inhibitors
5.1.3.2. Cell Therapy and Gene Therapy
5.1.3.3. Oncolytic Virus Therapy
5.1.3.4. Immune System Modulators
5.1.4. Hormonal Therapy
5.2. Europe Oncology Drugs Market Outlook, by Indication, Value (US$ Bn), 2020-2033
5.2.1. Breast Cancer
5.2.2. Lung Cancer
5.2.3. Prostate Cancer
5.2.4. Multiple Myeloma
5.2.5. Colorectal Cancer
5.2.6. Non-Hodgkin's Lymphoma
5.2.7. Kidney Cancer
5.2.8. Chronic lymphocytic Leukaemia
5.2.9. Melanoma
5.2.10. Others
5.3. Europe Oncology Drugs Market Outlook, by Route of Administration, Value (US$ Bn), 2020-2033
5.3.1. Oral
5.3.2. Injectable
5.4. Europe Oncology Drugs Market Outlook, by Distribution Channel, Value (US$ Bn), 2020-2033
5.4.1. Hospital Pharmacies
5.4.2. Retail Pharmacies
5.4.3. Others
5.5. Europe Oncology Drugs Market Outlook, by Country, Value (US$ Bn), 2020-2033
5.5.1. Germany Oncology Drugs Market Outlook, by Drug Class, 2020-2033
5.5.2. Germany Oncology Drugs Market Outlook, by Indication, 2020-2033
5.5.3. Germany Oncology Drugs Market Outlook, by Route of Administration, 2020-2033
5.5.4. Germany Oncology Drugs Market Outlook, by Distribution Channel, 2020-2033
5.5.5. Italy Oncology Drugs Market Outlook, by Drug Class, 2020-2033
5.5.6. Italy Oncology Drugs Market Outlook, by Indication, 2020-2033
5.5.7. Italy Oncology Drugs Market Outlook, by Route of Administration, 2020-2033
5.5.8. Italy Oncology Drugs Market Outlook, by Distribution Channel, 2020-2033
5.5.9. France Oncology Drugs Market Outlook, by Drug Class, 2020-2033
5.5.10. France Oncology Drugs Market Outlook, by Indication, 2020-2033
5.5.11. France Oncology Drugs Market Outlook, by Route of Administration, 2020-2033
5.5.12. France Oncology Drugs Market Outlook, by Distribution Channel, 2020-2033
5.5.13. U.K. Oncology Drugs Market Outlook, by Drug Class, 2020-2033
5.5.14. U.K. Oncology Drugs Market Outlook, by Indication, 2020-2033
5.5.15. U.K. Oncology Drugs Market Outlook, by Route of Administration, 2020-2033
5.5.16. U.K. Oncology Drugs Market Outlook, by Distribution Channel, 2020-2033
5.5.17. Spain Oncology Drugs Market Outlook, by Drug Class, 2020-2033
5.5.18. Spain Oncology Drugs Market Outlook, by Indication, 2020-2033
5.5.19. Spain Oncology Drugs Market Outlook, by Route of Administration, 2020-2033
5.5.20. Spain Oncology Drugs Market Outlook, by Distribution Channel, 2020-2033
5.5.21. Russia Oncology Drugs Market Outlook, by Drug Class, 2020-2033
5.5.22. Russia Oncology Drugs Market Outlook, by Indication, 2020-2033
5.5.23. Russia Oncology Drugs Market Outlook, by Route of Administration, 2020-2033
5.5.24. Russia Oncology Drugs Market Outlook, by Distribution Channel, 2020-2033
5.5.25. Rest of Europe Oncology Drugs Market Outlook, by Drug Class, 2020-2033
5.5.26. Rest of Europe Oncology Drugs Market Outlook, by Indication, 2020-2033
5.5.27. Rest of Europe Oncology Drugs Market Outlook, by Route of Administration, 2020-2033
5.5.28. Rest of Europe Oncology Drugs Market Outlook, by Distribution Channel, 2020-2033
5.6. BPS Analysis/Market Attractiveness Analysis
6. Asia Pacific Oncology Drugs Market Outlook, 2020 - 2033
6.1. Asia Pacific Oncology Drugs Market Outlook, by Drug Class, Value (US$ Bn), 2020-2033
6.1.1. Chemotherapy
6.1.1.1. Alkylating Agents
6.1.1.2. Antimetabolites
6.1.1.3. Anti-tumour Antibiotics
6.1.1.4. Topoisomerase Inhibitors
6.1.1.5. Mitotic Inhibitors
6.1.1.6. Others
6.1.2. Targeted Therapy
6.1.2.1. Monoclonal Antibodies
6.1.2.2. Small molecule Inhibitors
6.1.3. Immunotherapy
6.1.3.1. Immune Checkpoint Inhibitors
6.1.3.2. Cell Therapy and Gene Therapy
6.1.3.3. Oncolytic Virus Therapy
6.1.3.4. Immune System Modulators
6.1.4. Hormonal Therapy
6.2. Asia Pacific Oncology Drugs Market Outlook, by Indication, Value (US$ Bn), 2020-2033
6.2.1. Breast Cancer
6.2.2. Lung Cancer
6.2.3. Prostate Cancer
6.2.4. Multiple Myeloma
6.2.5. Colorectal Cancer
6.2.6. Non-Hodgkin's Lymphoma
6.2.7. Kidney Cancer
6.2.8. Chronic lymphocytic Leukaemia
6.2.9. Melanoma
6.2.10. Others
6.3. Asia Pacific Oncology Drugs Market Outlook, by Route of Administration, Value (US$ Bn), 2020-2033
6.3.1. Oral
6.3.2. Injectable
6.4. Asia Pacific Oncology Drugs Market Outlook, by Distribution Channel, Value (US$ Bn), 2020-2033
6.4.1. Hospital Pharmacies
6.4.2. Retail Pharmacies
6.4.3. Others
6.5. Asia Pacific Oncology Drugs Market Outlook, by Country, Value (US$ Bn), 2020-2033
6.5.1. China Oncology Drugs Market Outlook, by Drug Class, 2020-2033
6.5.2. China Oncology Drugs Market Outlook, by Indication, 2020-2033
6.5.3. China Oncology Drugs Market Outlook, by Route of Administration, 2020-2033
6.5.4. China Oncology Drugs Market Outlook, by Distribution Channel, 2020-2033
6.5.5. Japan Oncology Drugs Market Outlook, by Drug Class, 2020-2033
6.5.6. Japan Oncology Drugs Market Outlook, by Indication, 2020-2033
6.5.7. Japan Oncology Drugs Market Outlook, by Route of Administration, 2020-2033
6.5.8. Japan Oncology Drugs Market Outlook, by Distribution Channel, 2020-2033
6.5.9. South Korea Oncology Drugs Market Outlook, by Drug Class, 2020-2033
6.5.10. South Korea Oncology Drugs Market Outlook, by Indication, 2020-2033
6.5.11. South Korea Oncology Drugs Market Outlook, by Route of Administration, 2020-2033
6.5.12. South Korea Oncology Drugs Market Outlook, by Distribution Channel, 2020-2033
6.5.13. India Oncology Drugs Market Outlook, by Drug Class, 2020-2033
6.5.14. India Oncology Drugs Market Outlook, by Indication, 2020-2033
6.5.15. India Oncology Drugs Market Outlook, by Route of Administration, 2020-2033
6.5.16. India Oncology Drugs Market Outlook, by Distribution Channel, 2020-2033
6.5.17. Southeast Asia Oncology Drugs Market Outlook, by Drug Class, 2020-2033
6.5.18. Southeast Asia Oncology Drugs Market Outlook, by Indication, 2020-2033
6.5.19. Southeast Asia Oncology Drugs Market Outlook, by Route of Administration, 2020-2033
6.5.20. Southeast Asia Oncology Drugs Market Outlook, by Distribution Channel, 2020-2033
6.5.21. Rest of SAO Oncology Drugs Market Outlook, by Drug Class, 2020-2033
6.5.22. Rest of SAO Oncology Drugs Market Outlook, by Indication, 2020-2033
6.5.23. Rest of SAO Oncology Drugs Market Outlook, by Route of Administration, 2020-2033
6.5.24. Rest of SAO Oncology Drugs Market Outlook, by Distribution Channel, 2020-2033
6.6. BPS Analysis/Market Attractiveness Analysis
7. Latin America Oncology Drugs Market Outlook, 2020 - 2033
7.1. Latin America Oncology Drugs Market Outlook, by Drug Class, Value (US$ Bn), 2020-2033
7.1.1. Chemotherapy
7.1.1.1. Alkylating Agents
7.1.1.2. Antimetabolites
7.1.1.3. Anti-tumour Antibiotics
7.1.1.4. Topoisomerase Inhibitors
7.1.1.5. Mitotic Inhibitors
7.1.1.6. Others
7.1.2. Targeted Therapy
7.1.2.1. Monoclonal Antibodies
7.1.2.2. Small molecule Inhibitors
7.1.3. Immunotherapy
7.1.3.1. Immune Checkpoint Inhibitors
7.1.3.2. Cell Therapy and Gene Therapy
7.1.3.3. Oncolytic Virus Therapy
7.1.3.4. Immune System Modulators
7.1.4. Hormonal Therapy
7.2. Latin America Oncology Drugs Market Outlook, by Indication, Value (US$ Bn), 2020-2033
7.2.1. Breast Cancer
7.2.2. Lung Cancer
7.2.3. Prostate Cancer
7.2.4. Multiple Myeloma
7.2.5. Colorectal Cancer
7.2.6. Non-Hodgkin's Lymphoma
7.2.7. Kidney Cancer
7.2.8. Chronic lymphocytic Leukaemia
7.2.9. Melanoma
7.2.10. Others
7.3. Latin America Oncology Drugs Market Outlook, by Route of Administration, Value (US$ Bn), 2020-2033
7.3.1. Oral
7.3.2. Injectable
7.4. Latin America Oncology Drugs Market Outlook, by Distribution Channel, Value (US$ Bn), 2020-2033
7.4.1. Hospital Pharmacies
7.4.2. Retail Pharmacies
7.4.3. Others
7.5. Latin America Oncology Drugs Market Outlook, by Country, Value (US$ Bn), 2020-2033
7.5.1. Brazil Oncology Drugs Market Outlook, by Drug Class, 2020-2033
7.5.2. Brazil Oncology Drugs Market Outlook, by Indication, 2020-2033
7.5.3. Brazil Oncology Drugs Market Outlook, by Route of Administration, 2020-2033
7.5.4. Brazil Oncology Drugs Market Outlook, by Distribution Channel, 2020-2033
7.5.5. Mexico Oncology Drugs Market Outlook, by Drug Class, 2020-2033
7.5.6. Mexico Oncology Drugs Market Outlook, by Indication, 2020-2033
7.5.7. Mexico Oncology Drugs Market Outlook, by Route of Administration, 2020-2033
7.5.8. Mexico Oncology Drugs Market Outlook, by Distribution Channel, 2020-2033
7.5.9. Argentina Oncology Drugs Market Outlook, by Drug Class, 2020-2033
7.5.10. Argentina Oncology Drugs Market Outlook, by Indication, 2020-2033
7.5.11. Argentina Oncology Drugs Market Outlook, by Route of Administration, 2020-2033
7.5.12. Argentina Oncology Drugs Market Outlook, by Distribution Channel, 2020-2033
7.5.13. Rest of LATAM Oncology Drugs Market Outlook, by Drug Class, 2020-2033
7.5.14. Rest of LATAM Oncology Drugs Market Outlook, by Indication, 2020-2033
7.5.15. Rest of LATAM Oncology Drugs Market Outlook, by Route of Administration, 2020-2033
7.5.16. Rest of LATAM Oncology Drugs Market Outlook, by Distribution Channel, 2020-2033
7.6. BPS Analysis/Market Attractiveness Analysis
8. Middle East & Africa Oncology Drugs Market Outlook, 2020 - 2033
8.1. Middle East & Africa Oncology Drugs Market Outlook, by Drug Class, Value (US$ Bn), 2020-2033
8.1.1. Chemotherapy
8.1.1.1. Alkylating Agents
8.1.1.2. Antimetabolites
8.1.1.3. Anti-tumour Antibiotics
8.1.1.4. Topoisomerase Inhibitors
8.1.1.5. Mitotic Inhibitors
8.1.1.6. Others
8.1.2. Targeted Therapy
8.1.2.1. Monoclonal Antibodies
8.1.2.2. Small molecule Inhibitors
8.1.3. Immunotherapy
8.1.3.1. Immune Checkpoint Inhibitors
8.1.3.2. Cell Therapy and Gene Therapy
8.1.3.3. Oncolytic Virus Therapy
8.1.3.4. Immune System Modulators
8.1.4. Hormonal Therapy
8.2. Middle East & Africa Oncology Drugs Market Outlook, by Indication, Value (US$ Bn), 2020-2033
8.2.1. Breast Cancer
8.2.2. Lung Cancer
8.2.3. Prostate Cancer
8.2.4. Multiple Myeloma
8.2.5. Colorectal Cancer
8.2.6. Non-Hodgkin's Lymphoma
8.2.7. Kidney Cancer
8.2.8. Chronic lymphocytic Leukaemia
8.2.9. Melanoma
8.2.10. Others
8.3. Middle East & Africa Oncology Drugs Market Outlook, by Route of Administration, Value (US$ Bn), 2020-2033
8.3.1. Oral
8.3.2. Injectable
8.4. Middle East & Africa Oncology Drugs Market Outlook, by Distribution Channel, Value (US$ Bn), 2020-2033
8.4.1. Hospital Pharmacies
8.4.2. Retail Pharmacies
8.4.3. Others
8.5. Middle East & Africa Oncology Drugs Market Outlook, by Country, Value (US$ Bn), 2020-2033
8.5.1. GCC Oncology Drugs Market Outlook, by Drug Class, 2020-2033
8.5.2. GCC Oncology Drugs Market Outlook, by Indication, 2020-2033
8.5.3. GCC Oncology Drugs Market Outlook, by Route of Administration, 2020-2033
8.5.4. GCC Oncology Drugs Market Outlook, by Distribution Channel, 2020-2033
8.5.5. South Africa Oncology Drugs Market Outlook, by Drug Class, 2020-2033
8.5.6. South Africa Oncology Drugs Market Outlook, by Indication, 2020-2033
8.5.7. South Africa Oncology Drugs Market Outlook, by Route of Administration, 2020-2033
8.5.8. South Africa Oncology Drugs Market Outlook, by Distribution Channel, 2020-2033
8.5.9. Egypt Oncology Drugs Market Outlook, by Drug Class, 2020-2033
8.5.10. Egypt Oncology Drugs Market Outlook, by Indication, 2020-2033
8.5.11. Egypt Oncology Drugs Market Outlook, by Route of Administration, 2020-2033
8.5.12. Egypt Oncology Drugs Market Outlook, by Distribution Channel, 2020-2033
8.5.13. Nigeria Oncology Drugs Market Outlook, by Drug Class, 2020-2033
8.5.14. Nigeria Oncology Drugs Market Outlook, by Indication, 2020-2033
8.5.15. Nigeria Oncology Drugs Market Outlook, by Route of Administration, 2020-2033
8.5.16. Nigeria Oncology Drugs Market Outlook, by Distribution Channel, 2020-2033
8.5.17. Rest of Middle East Oncology Drugs Market Outlook, by Drug Class, 2020-2033
8.5.18. Rest of Middle East Oncology Drugs Market Outlook, by Indication, 2020-2033
8.5.19. Rest of Middle East Oncology Drugs Market Outlook, by Route of Administration, 2020-2033
8.5.20. Rest of Middle East Oncology Drugs Market Outlook, by Distribution Channel, 2020-2033
8.6. BPS Analysis/Market Attractiveness Analysis
9. Competitive Landscape
9.1. Company Vs Segment Heatmap
9.2. Company Market Share Analysis, 2025
9.3. Competitive Dashboard
9.4. Company Profiles
9.4.1. GlaxoSmithKline
9.4.1.1. Company Overview
9.4.1.2. Product Portfolio
9.4.1.3. Financial Overview
9.4.1.4. Business Strategies and Developments
9.4.2. AstraZeneca plc
9.4.3. AbbVie
9.4.4. Pfizer Inc.
9.4.5. Amgen Inc
9.4.6. Gilead Sciences, Inc
9.4.7. Hoffmann-La Roche Ltd
9.4.8. Bristol-Myers Squibb Company (Celgene Corp)
9.4.9. Novartis AG
9.4.10. Johnson & Johnson Merck & Co.
9.4.11. Eli Lilly and Company
9.4.12. Sanofi S.A
9.4.13. Bayer AG
10. Appendix
10.1. Research Methodology
10.2. Report Assumptions
10.3. Acronyms and Abbreviations